Search results
Results from the WOW.Com Content Network
Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer. [ 1 ] [ 5 ] [ 7 ] It is an inhibitor of tropomyosin kinase receptors TrkA , TrkB , and TrkC . [ 8 ] [ 9 ] [ 10 ] It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013.
Cobimetinib, sold under the brand name Cotellic, is an anti-cancer medication used to treat melanoma and histiocytic neoplasms. [2] [8] Cobimetinib is a MEK inhibitor. [2] ...
The project publishes drug reports. The first three reports covered Statins to reduce high cholesterol, heartburn drugs, and NSAIDs commonly used to treat arthritis. The project covers over 20 conditions and the most widely used drugs. [5] The reports are published in web versions and two-page PDF summaries in English and Spanish.
Tyrosine kinase inhibitor (TKI) with selective activity against RET, VEGFR-2 and EGFR: Medullary thyroid cancer. Diarrhoea, hypertension, QT interval prolongation, depression, electrolyte anomalies, hypothyroidism and GI perforation (uncommon). 2.3 mTOR inhibitors: Everolimus: PO: mTOR inhibitor.
Intense heating will cause denaturation and coagulation of cellular proteins, rapidly killing cells within a tumour. More prolonged moderate heating to temperatures just a few degrees above normal (39.5 °C) can cause more subtle changes. A mild heat treatment combined with other stresses can cause cell death by apoptosis.
Cediranib (AZD-2171; tentative trade name Recentin) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. [1] [2] [3] The drug is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.
Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. [5] Inappropriate activation of the pathway has been shown to occur in many cancers. [ 5 ] In June 2018 it was approved by the FDA in combination with encorafenib for the treatment of patients with unresectable or metastatic BRAF V600E or V600K ...
PI3K inhibitors block the PI3K/AKT/mTOR pathway and thus slow down cancer growth. [2] [3] They are examples of a targeted therapy. [4] While PI3K inhibitors are an effective treatment, they can have very severe side effects and are therefore only used if other treatments have failed or are not suitable. [5] [6]